SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01120262

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy

RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.

NCT01120262 Prostate Cancer
MeSH:Prostatic Neoplasms
HPO:Prostate cancer Prostate neoplasm

3 Interventions

Name: gene expression analysis

Type: Genetic

Name: polymorphism analysis

Type: Genetic

Name: laboratory biomarker analysis

Type: Other


Primary Outcomes

Measure: Serum PSA values at 7 months

Time: 7 months

Measure: Role of genetic variation in response to therapy

Time: baseline

Time Perspective: Retrospective

Cohort


There is one SNP

SNPs


1 S9346A

S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. --- S9346A ---



HPO Nodes


HPO: